138742-43-5 (A 72517)
1
Identification
Name |
A 72517
|
Formula |
C35H55N5O6S2
|
MW |
705.97 |
CAS No. |
138742-43-5 |
EINECS |
|
Smiles |
O=C(N(NC(C(CS(=O)(N1CCN(C)CC1)=O)CC2=CC=CC=C2)=O)[[email protected]@H](CC3CCCCC3)[[email protected]@H](O)[[email protected]@H](O)CC(C)C)CCC4=CSC=N4 |
Synonyms |
Zankiren; 2-benzyl-N'-((2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl)-3-((4-methylpiperazin-1-yl)sulfonyl)-N'-(3-(thiazol-4-yl)propanoyl)propanehydrazide |
InChI |
InChI=1S/C35H55N5O6S2/c1-26(2)20-32(41)34(43)31(22-28-12-8-5-9-13-28)40(33(42)15-14-30-23-47-25-36-30)37-35(44)29(21-27-10-6-4-7-11-27)24-48(45,46)39-18-16-38(3)17-19-39/h4,6-7,10-11,23,25-26,28-29,31-32,34,41,43H,5,8-9,12-22,24H2,1-3H3,(H,37,44)/t29?,31-,32-,34+/m0/s1 |
2
Introduction
Renin Inhibitor
Background Information
3
Protocol(Only for Reference)
Cell Experiment
Animal Experiment
4
Physical and Chemical Properties
Appearance: |
EBNumber:EB000023614 |
Storage condition
Solubility
5
Mechanism and Indication
6
Clinical Information
Product Name |
Sponsor & Collaborators |
Indications |
Start Date |
End Date |
Phase |
A 72517
|
- |
|
|
|
No Development Reported |
10
Related Products
Other Forms of 138742-43-5
Recommended Compounds in
Recommended Compounds in Same Indication